GRAIL showcases methylation platform performance across cancer continuum with new data

At the American Association for Cancer Research (AACR) 2023 Annual Meeting, GRAIL, LLC presented new data showcasing the performance of its methylation platform to detect cancer across the early- and post-diagnosis settings.

In the early-diagnosis setting, GRAIL presented real-world case studies of the Galleri multi-cancer early detection (MCED) test that demonstrate how Galleri led to early detection and treatment of cancer in asymptomatic individuals and directed diagnostic evaluation. In these instances, the Galleri test allowed the cancers to be detected in early stages and before clinical presentation.

In the post-diagnosis setting, analytical validation data shows how GRAIL’s targeted methylation technology platform can be used for diagnostic decision support to aid in achieving timely and cost-effective management of patients after a cancer diagnosis. GRAIL presented results from an analytical validation of its research-use-only technology solution to accelerate cancer research in the post-diagnosis setting. launched as an offering to biopharmaceutical companies in January 2023.

Josh Ofman, MD, MSHS, president at GRAIL said, “In addition to case studies of our Galleri® multi-cancer early detection test in clinical practice, and demonstrating the unmet need for patients presenting with non-specific symptoms suggestive of cancer, we are excited to share results evaluating the performance of our new research-use only, methylation-based solution for post-diagnosis applications.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>